OnCo

Create your OnCo account

One account keeps your watchlist, saved views and cancer choice in sync across your devices, and lets OnCo alert you when a trial or treatment you follow changes. No password: we email you a sign-in link.

Account creation is being switched on. Until then, press Watch on any page and your list stays in this browser.

Living with cancer· Appointment prep

Appointment sheet: Non-Hodgkin lymphoma (all types)

One page to bring and write on: your details, the questions for Non-Hodgkin lymphoma (all types) plus your own, the words you may hear, what to bring, the treatments the standard of care names, and room for the answers and agreed next steps. What you type stays in this browser. Print it or save it as a PDF. New to all this? Start with the first 60 days. Orientation, not medical advice.

Tick the questions to print

All of this cancer's questions start ticked. Untick what does not apply; ticks are kept in this browser. .

Your own questions

Shared with the prep pack, so questions you add there appear here too.

Print or save as PDF

Use (or Ctrl+P, Cmd+P on a Mac). To keep a copy, choose Save as PDF as the destination in the print dialog. Only the sheet prints; the controls stay on screen. Your typed notes print where you typed them; empty fields print as ruled lines to write on.

Appointment sheet

Non-Hodgkin lymphoma (all types)

Prepared with OnCo (onco.cc/prep/non-hodgkin-lymphoma/). Orientation, not medical advice; your team knows your case.

My details

Name
Date of appointment
Hospital and clinician
Who is coming with me

What I know, what is unclear, changes to discuss

Saved in this browser
What I know so far
What is unclear to me
Changes since last time

My questions

17 on the sheet
Newly diagnosed
  1. 1.What is my exact diagnosis, stage, and grade, and which tests established them?
  2. 2.Which biomarkers have been tested on my tumour (for example Immunophenotypethat assigns the subtype, MYC, BCL2 and BCL6 rearrangements, Ki-67 proliferation index, Interim and end-of-treatment PET, Cell of originin DLBCL), and what were the results?
  3. 3.Which subtype is my cancer, and does that change the recommended treatment?
  4. 4.Is germline (inherited) genetic testing recommended for me or my family?
Aggressive B-cell (DLBCL and related)
  1. 5.For my situation (aggressive b-cell (dlbcl and related)), which of the standard options do you recommend and why?
  2. 6.Am I a candidate for Rituximab, Polatuzumab vedotin, and what side effects should I expect?
Indolent B-cell (follicular, marginal zone)
  1. 7.For my situation (indolent b-cell (follicular, marginal zone)), which of the standard options do you recommend and why?
  2. 8.Am I a candidate for Rituximab, Bendamustine, and what side effects should I expect?
Mantle cell lymphoma and CLL
  1. 9.For my situation (mantle cell lymphoma and cll), which of the standard options do you recommend and why?
  2. 10.Am I a candidate for Ibrutinib, Venetoclax, and what side effects should I expect?
T-cell lymphomas
  1. 11.For my situation (t-cell lymphomas), which of the standard options do you recommend and why?
  2. 12.Am I a candidate for Brentuximab vedotin, and what side effects should I expect?
Any stage
  1. 13.Are there clinical trials I could join, for example of Glofitamab, Epcoritamab, Mosunetuzumab, Obecabtagene autoleucel?
  2. 14.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
  3. 15.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
  4. 16.I read that “Relapsed T-cell lymphomas still lack effective options”. How does that affect my plan?
  5. 17.I read that “Access to CAR-T and bispecifics outside high-income countries”. How does that affect my plan?

Tests and results to bring

Biomarker results to ask for: Immunophenotype (CD20, CD5, CD10, CD30 and others) that assigns the subtype, MYC, BCL2 and BCL6 rearrangements (high-grade B-cell lymphoma), Ki-67 proliferation index, Interim and end-of-treatment PET (Deauville score), Cell of origin (germinal centre versus activated B-cell) in DLBCL.

Scans and tests linked to this cancer: Flow cytometers, Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC), Capsule endoscopy (PillCam, EndoCapsule, CapsoCam).

Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.

The treatments I may be offered

  • Aggressive B-cell (DLBCL and related): Curative immunochemotherapy (R-CHOP or Pola-R-CHP); CAR-T or bispecific antibodies at relapse. See the DLBCL page. (Rituximab, Polatuzumab vedotin)
  • Indolent B-cell (follicular, marginal zone): Watch and wait when asymptomatic; rituximab alone or with bendamustine or CHOP when treatment is needed; bispecifics and CAR-T for later relapses. See the follicular lymphoma page. (Rituximab, Bendamustine)
  • Mantle cell lymphoma and CLL: BTK inhibitors and venetoclax-based regimens have largely replaced chemotherapy. See the mantle cell and CLL pages. (Ibrutinib, Venetoclax)
  • T-cell lymphomas: CHOP-based chemotherapy, brentuximab vedotin for CD30-positive disease, transplant in first remission for fit patients. See the peripheral T-cell lymphoma page. (Brentuximab vedotin)

From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.

Answers and next steps

Saved in this browser
What I was told
Agreed next steps, dates and who to call